Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting
  • CME

Amy E. DeZern, MD, MHS
Srdan Verstovsek, MD, PhD
Released: February 16, 2021
Back Next

Myeloproliferative Neoplasm and Myelodysplastic Syndromes Studies at ASH 2020

Key Studies in MPN and MDS

In this module, Srdan Verstovsek, MD, PhD, and Amy E. DeZern, MD, MHS, offer an overview of some of the myeloproliferative neoplasm (MPNs) and myelodysplastic syndromes (MDS) studies presented at the 2020 ASH Annual Meeting. The studies covered first-line and second-line treatments for MPN and MDS as well as therapies to treat the anemia associated with these diseases.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets that can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue